3 potential coronavirus vaccines showing promise in early tests

3 potential coronavirus vaccines showing promise in early tests

3 potential coronavirus vaccines showing promise in early tests

The Chinese effort began on March 16 - the same day as the United States announcement - and is expected to continue until the end of the year, according to a filing in the country's Clinical Trial Registry, dated March 17.

World Health Organisation (WHO) has issued a list of 70 vaccines now under development across the globe to treat coronavirus.

Chinese authorities had earlier approved one vaccine developed by Sinovac Biotech to go in for clinical trial.

The other two being tested in humans are treatments developed separately by USA drugmakers - and Inovio Pharmaceuticals, according to a World Health Organization document.

UQ's vaccine program co-leader Dr Keith Chappell says the trial will establish a critical package of data ahead of human clinical trials later this year.

Meanwhile, The effectiveness of a University of Queensland (UQ) vaccine against the coronavirus is about to be tested in a biosecurity facility in the Netherlands.

In the US, a shot made by the National Institutes of Health and Moderna Inc. isn't far behind.

Volunteer recruitment for the vaccine began on Thursday. Hot on their heels, US-based biotech startups Inovio Pharmaceuticals and Moderna have both started human testing as well.

US company Inovio Pharmaceuticals is also conducting human trials and is working with Chinese researchers to begin a study with the drug in China. The next step would be a phase III trial where the vaccine is tested on a much larger group of people. Pharmaceutical giants like Pfizer Inc. and Sanofi have vaccine candidates in the preclinical stages, according to the World Health Organization document.

A vaccine is the entry way to the new normal across the planet.

Industry experts are saying it could take as long as a year and a half before a vaccine is readily available and this time frame is already pushing it. Russian Federation is the main source of "import" of the virus into China. "Having committed to providing unconditional support to fight against the global epidemic, CanSinoBIO is determined to launch our vaccine product candidate as soon as possible with no compromise on quality and safety", Xuefeng Yu, Chairman, and CEO of CanSinoBIO said.

Latest News